Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Male Sexual Response: Erection & Ejaculation

Male Sexual Response: Erection & Ejaculation

Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Oral Drug Delivery Systems: Delayed-Release Systems

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...

Sperm Transport

Sperm Transport

The journey of sperm from its origin to the point of ejaculation begins within the seminiferous tubules of the testis. Here, Sertoli cells produce fluid that propels non-motile sperm through a series of conduits, starting with the straight tubules leading to the rete testis. This interconnected network of tubules acts as the initial pathway for sperm, guiding them into the efferent ductules and then into the epididymis for maturation.
The maturation phase occurs in the epididymis, where sperm...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Unfinished Business of Defining Premature Ejaculation: The Need for Targeted Research.

Sexual medicine reviews·2022

Same author

Disorders of Ejaculation: An AUA/SMSNA Guideline.

The Journal of urology·2021

Same author

Advances and Missteps in Diagnosing Premature Ejaculation: Analysis and Future Directions.

The journal of sexual medicine·2021

Same author

Response to Letter to the Editor Regarding "Cligosiban for Premature Ejaculation: Success, Failure, or Insufficiently Tested?"

The journal of sexual medicine·2019

Same author

Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for Treatment of Symptoms Associated With Androgen Deficiency.

The journal of sexual medicine·2017

Same author

Changes in the Effects of Peyronie's Disease After Treatment With Collagenase Clostridium histolyticum: Male Patients and Their Female Partners.

Sexual medicine·2017

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Dapoxetine for premature ejaculation.

Chris G McMahon¹

¹Australian Centre for Sexual Health, Suite 2-4, Berry Road Medical Centre, 1a Berry Road, St Leonards, NSW 2065, Australia. cmcmahon@acsh.com.au

Expert Opinion on Pharmacotherapy

|June 15, 2010

Summary

This summary is machine-generated.

Dapoxetine offers an effective and safe on-demand treatment for premature ejaculation (PE), addressing a significant unmet need in male sexual health. This selective serotonin reuptake inhibitor (SSRI) improves ejaculatory control and patient-reported outcomes.

Related Experiment Videos

Last Updated: Jun 12, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

Sexual Medicine
Pharmacology
Urology

Background:

Premature ejaculation (PE) is a prevalent male sexual disorder with significant psychological impact.
Current treatments often rely on off-label selective serotonin reuptake inhibitors (SSRIs), highlighting an unmet medical need.
The development of an approved medication for PE is crucial.

Purpose of the Study:

To review the efficacy and safety of dapoxetine for the treatment of premature ejaculation (PE).
To provide insights into the epidemiology, pathophysiology, and current drug treatments for PE.
To evaluate dapoxetine's pharmacokinetic profile and drug interactions.

Main Methods:

A comprehensive literature search was conducted for studies on dapoxetine from 1994-2010.
Included pharmacokinetic, animal, and human Phase I-III efficacy and safety studies.
Five randomized, double-blind, placebo-controlled trials involving 6,081 men were analyzed.

Main Results:

Dapoxetine (30 and 60 mg) significantly improved intravaginal ejaculatory latency time (IELT) and patient-reported outcomes compared to placebo (p < 0.001).
Rapid absorption and elimination with minimal accumulation were observed.
Common adverse events included nausea, dizziness, and headache, with no SSRI class-related effects noted.

Conclusions:

Dapoxetine is the first medication specifically developed and approved for PE.
It represents a significant advancement in sexual medicine, offering an effective and safe treatment option.
Dapoxetine provides a valuable therapeutic choice for men experiencing premature ejaculation.